| Identification | Back Directory | [Name]
2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione 1-[O-(2-methylbenzoyl)oxime] | [CAS]
321688-88-4 | [Synonyms]
Poloxin
Polo-like Kinase Inhibitor V, Poloxin
Polo-like Kinase Inhibitor V, Poloxin - CAS 321688-88-4 - Calbiochem
(Z)-2-Isopropyl-5-methyl-4-(((2-methylbenzoyl)oxy)imino)cyclohexa-2,5-dienone
2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione 1-[O-(2-methylbenzoyl)oxime]
2-Methyl-5-(1-methylethyl)-1-[O-(2-methylbenzoyl)oxime]-2,5-Cyclohexadiene-1,4-dione
2,5-Cyclohexadiene-1,4-dione, 2-methyl-5-(1-methylethyl)-, 1-[O-(2-methylbenzoyl)oxime] | [Molecular Formula]
C18H19NO3 | [MDL Number]
MFCD00534351 | [MOL File]
321688-88-4.mol | [Molecular Weight]
297.35 |
| Chemical Properties | Back Directory | [Boiling point ]
418.6±55.0 °C(Predicted) | [density ]
1.11 | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble5mg/mL (clear solution, warmed) | [form ]
Yellow solid | [color ]
white to beige | [InChI]
1S/C18H19NO3/c1-11(2)15-10-16(13(4)9-17(15)20)19-22-18(21)14-8-6-5-7-12(14)3/h5-11H,1-4H3/b19-16- | [InChIKey]
CMOJHDQJJPIVEC-MNDPQUGUSA-N |
| Hazard Information | Back Directory | [Uses]
Poloxin is a non-ATP competitive Polo-like Kinase 1 (Plk1) inhibitor that targets the polo-box domain. | [in vivo]
Poloxin (40 mg/kg) decreases the proliferation of MDA-MB-231 cells, and surpresses the growth of the tumor nude mice bearing established xenografts of MDA-MB-231[1]. | [IC 50]
PLK1 PBD: 4.8 μM (IC50); PLK2 PBD: 18.7 μM (IC50); PLK3 PBD: 53.9 μM (IC50) |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|